ControlRad announced today that it received FDA 510(k) clearance for the use of its ControlRad Trace on OEC 9900 Mobile C-arms.
Atlanta-based Controlrad’s Trace system is designed for reducing radiation in fluoroscopically guided procedures.
According to a news release, the ControlRad Trace can be retrofitted onto existing mobile C-arms with its proprietary semi-transparent filter, tablet and image processing technology. That allows it to reduce the barrier to adopting technology in order to reduce unnecessary radiation without compromising image quality or workflow.
“This additional FDA clearance allows us to offer the critically-important protection of our radiation reduction technology to even more patients and staff in need of mobile C-arm related procedures,” ControlRad president Chris Fair said in the release.
Additionally, the company announced that it closed a Series C financing round for an undisclosed amount. Current investor Questa Capital led the round.
“We are extremely appreciative for the additional investment from Questa and also pleased to welcome new investor Windham Ventures to our investor group,” ControlRad CEO Guillaume Bailliard said. “We are excited to further build our commercial reach to advance our efforts to help save patients and clinical staff from the harmful effects of excessive radiation.”